Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Celgene Corporation
CELG
Healthcare
Drug Manufacturers - Major
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma...
drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:CELG)
New Post
View:
Posts & Comments
Threaded Posts
(0)
•••
goregil
X
View Profile
View Bullboard History
Post by
goregil
on Feb 10, 2019 12:09am
Seeking another celgene
Seeking a penny stock that could explode into a several hundred dollar stock .theralase v.tlt may fit the bill v.tlt is a undiscovered small Canadian with the potential to cure bladder cancer as well
...more
(0)
•••
Ichimek
X
View Profile
View Bullboard History
Post by
Ichimek
on Jul 06, 2018 1:25pm
Old Japanese Technique Ichimoku soon may give buy signal
Check Out Ceglene Corporation (CELG) Technical Analysis with old Japanese technique Ichimoku
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 24, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(72)
•••
paths
X
View Profile
View Bullboard History
Comment by
paths
on May 22, 2018 12:24am
RE:Buybacks?
The market has decided right or wrong they made a bad purchase with Juno, so if that was 9 bill. wasted, the market has now taken 18 bill. off of the market cap, so good grief it should stabilize soon
...more
(0)
•••
JOHNNYBOYO1
X
View Profile
View Bullboard History
Post by
JOHNNYBOYO1
on May 18, 2018 3:33pm
Buybacks?
Is Mgmt going to step in and do anything as this thing loses 1-2% daily?
(0)
•••
BluSignals
X
View Profile
View Bullboard History
Post by
BluSignals
on May 07, 2018 11:50am
Why CELG Keeps Falling: BluSignals Indicators
Many traders and investors continue to anticipate a turn in direction for this biotech company. However, there are several pieces of data which highlight a negative trend. From product
...more
(11)
•••
IckySticky
X
View Profile
View Bullboard History
Post by
IckySticky
on Apr 04, 2018 8:05am
ARQL 3 bux/share DO invest in a REAL INVESTMENT! Bye CELG
ArQule to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting ARQL | March 15, 2018 ArQule to Present Data
...more
(11)
•••
IckySticky
X
View Profile
View Bullboard History
Post by
IckySticky
on Apr 04, 2018 8:03am
i bought CELG to make money not LOSE im IN @ ARQL now READ
ArQule to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting ARQL | March 15, 2018 ArQule to Present Data
...more
(11)
•••
IckySticky
X
View Profile
View Bullboard History
Comment by
IckySticky
on Apr 04, 2018 8:01am
RE:Celgene Finalizes Acquisition of Juno Therapeutics
HAPPY TO SAY AFTER @ YEARS IM DUMPING MY SHARES IN THIS TRAIN WRECK .. youll never guess where i putting them in ARQL !! im up 45% this month alone ,,, take a look ArQule to Present Data
...more
(0)
•••
Bearbull17
X
View Profile
View Bullboard History
Post by
Bearbull17
on Mar 06, 2018 9:44am
Celgene Finalizes Acquisition of Juno Therapeutics
Celgene Finalizes Acquisition of Juno Therapeutics 06 Mar 2018 08:43 ET 08:43 AM EST, 03/06/2018 (MT Newswires) -- Celgene (CELG), a biotech company, said early Tuesday it completed its $9 billion
...more
(0)
•••
NorFoster
X
View Profile
View Bullboard History
Post by
NorFoster
on Oct 26, 2017 10:07am
Chaos continue for CELG
https://alphastreet.com/b0662389 After halting the trials recently, Celgene today had cut down the outlook. Disappointing outlook (both FY17 and 2020 long-term targets) from Celgene.
(0)
•••
NorFoster
X
View Profile
View Bullboard History
Post by
NorFoster
on Oct 20, 2017 11:22am
Celgene - Financial impact of stopping Crohn's disease trial
Many people will not know the financial impact of Celgene stopping two trials for Crohn's disease. Celgene has announced that info in an SEC filing. https://alphastreet.com/bce290d5
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >